| Literature DB >> 36014406 |
Héctor A Peniche-Pavía1, Tereso J Guzmán2, Jesús M Magaña-Cerino3, Carmen M Gurrola-Díaz4, Axel Tiessen1.
Abstract
Maize is one of the most important crops for human and animal consumption and contains a chemical arsenal essential for survival: flavonoids. Moreover, flavonoids are well known for their beneficial effects on human health. In this review, we decided to organize the information about maize flavonoids into three sections. In the first section, we include updated information about the enzymatic pathway of maize flavonoids. We describe a total of twenty-one genes for the flavonoid pathway of maize. The first three genes participate in the general phenylpropanoid pathway. Four genes are common biosynthetic early genes for flavonoids, and fourteen are specific genes for the flavonoid subgroups, the anthocyanins, and flavone C-glycosides. The second section explains the tissue accumulation and regulation of flavonoids by environmental factors affecting the expression of the MYB-bHLH-WD40 (MBW) transcriptional complex. The study of transcription factors of the MBW complex is fundamental for understanding how the flavonoid profiles generate a palette of colors in the plant tissues. Finally, we also include an update of the biological activities of C3G, the major maize anthocyanin, including anticancer, antidiabetic, and antioxidant effects, among others. This review intends to disclose and integrate the existing knowledge regarding maize flavonoid pigmentation and its relevance in the human health sector.Entities:
Keywords: Zea mays L.; anthocyanins; biosynthesis; health benefits; pigmented maize; regulation
Mesh:
Substances:
Year: 2022 PMID: 36014406 PMCID: PMC9413827 DOI: 10.3390/molecules27165166
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Chemical structure of flavonoid subgroups and the basic C6-C3-C6 skeleton (2-phenyl-2H-chromene). A, B, and C refer to a specific ring of the flavonoid skeleton.
Summary of genes involved in the early steps of the maize flavonoid pathway.
| Gene Name | Locus | Enzyme/Protein Name | EC | Reference |
|---|---|---|---|---|
| ( | Phenylalanine ammonium lyase | 4.3.1.24 | [ | |
| ( | 8L | Cinnamic acid 4-hydroxylase | 1.14.14.91 | [ |
| 5 | 4-Coumarate CoA ligase | 6.2.1.12 | [ | |
| 4L | Chalcone synthase | 2.3.1.74 | [ | |
| 2L | Chalcone synthase | 2.3.1.74 | [ | |
| 1L | Chalcone isomerase | 5.5.1.6 | [ | |
| 2S | Flavonoid 3-dioxygenase | 1.14.11.9 | [ | |
| 5L | Flavonoid 3′-monooxygenase | 1.14.14.82 | [ |
EC code and locus were obtained from BRENDA [29] and MaizeGDB [30], respectively. The m* means multiple loci.
Figure 2Early genes in the flavonoid pathway. The flavonoid pathway begins with the transformation of phenylalanine to coumaroyl-CoA. The last steps end with the intravacuolar accumulation of acylated anthocyanins. The genes responsible for supplying the coumaroyl-CoA into the flavonoid pathway are phenylalanine ammonium lyase (ZmPAL, EC 4.3.1.24), cinnamic acid 4-hydroxylase (ZmC4H, EC 1.14.14.91), and 4-coumarate CoA ligase (Zm4CL, bm5, EC 6.2.1.12). The flavonoid genes are divided into early biosynthetic genes (EBGs) and late biosynthetic genes (LBGs). EBGs comprise four genes: chalcone synthase (ZmCHS, c2, EC 2.3.1.74), chalcone isomerase (ZmCHI, chi1, EC 5.5.1.6), flavonoid 3-dioxygenase (ZmF3H, fht1, EC 1.14.11.9), and flavonoid 3′-monooxygenase (ZmF3′H, pr1, EC 1.14.14.82). References: [30,32].
Figure 3Biosynthetic genes for maize anthocyanin pathway. After the formation of the dihydroflavonol, five enzymatic steps catalyze its biotransformation into acylated maize anthocyanins. Those genes are the following: dihydroflavonol 4-reductase (ZmDFR, a1, EC 1.1.1.219), anthocyanidin synthase (ZmANS, a2, EC 1.14.20.4), anthocyanidin 3-O-glucosyltransferase (ZmAGT, bz1, EC 2.4.1.115), malonyl-CoA: anthocyanin 3-O-glucoside-6′′-O-malonyltransferase (Zm3MAT, aat1, EC 2.3.1.171), and flavonoid 3′,5′-O-methyltransferase (ZmAOMT, EC 2.1.1.267). The glutathione S-transferase (ZmGST, bz2, EC 2.5.1.18) and multidrug resistance protein (ZmABCC3 and ZmABCC4, MRP3 and MRP 4, EC 7.6.2.2) are required to deliver them inside the vacuole. References: [30,32].
Summary of anthocyanin genes in the maize flavonoid pathway.
| Gene Name | Locus | Enzyme/Protein Name | EC | Reference |
|---|---|---|---|---|
| 5L | Flavonoid 3′-monooxygenase | 1.14.14.82 | [ | |
| 3L | Dihydroflavonol 4-reductase | 1.1.1.219 | [ | |
| -( | - | Leucoanthocyanidin reductase | 1.17.1.3 | - * |
| 5S | Anthocyanidin synthase | 1.14.20.4 | [ | |
| 9S | Anthocyanidin 3- | 2.4.1.115 | [ | |
| 1L | Malonyl-CoA: anthocyanin 3- | 2.3.1.171 | [ | |
| 4L | Anthocyanin S-adenosyl- | 2.1.1.267 | [ | |
| 4L | Glutathione-S-transferase | 2.5.1.18 | [ | |
| 9S | Multidrug resistance-associated protein or ATP-binding cassette transporter | 7.6.2.2 | [ |
* Not found yet in maize. EC code and locus were obtained from BRENDA [29] and MaizeGDB [30], respectively.
Figure 4The biosynthetic genes of flavonol and phlobaphenes. The flavanones naringenin and eriodyctiol are the starting substrates for the other flavonoid subgroups. Flavonol synthesis depends on flavanone 3-dioxygenase (ZmF3H, fht1, EC 1.14.11.9) and flavonol synthase (ZmFNS1, fns1, EC 1.14.20.5). Phlobaphene synthesis begins with the action of dihydroflavonol 4-reductase (ZmDFR, a1, EC 1.1.1.219) on flavanones, generating flavan-4-ol molecules that undergo a non-enzymatic polymerization into phlobaphenes. References: [8,30,32].
Summary of flavonol and flavone C-glycoside genes in the maize flavonoid pathway.
| Gene Name | Locus | Enzyme/Protein Name | EC | Reference |
|---|---|---|---|---|
| 5L | Flavonol synthase | 1.14.20.6 | [ | |
| 1S | Flavone synthase I | 1.14.20.5 | [ | |
| 10L | Flavone synthase II | 1.14.19.76 | [ | |
| fns1 ( | 9L | Flavanone 2-hydroxylase | 1.14.14.162 | [ |
| 6L | UDP-glucose:2-hydroxyflavanone C-glucosyltransferase | 2.4.1.360 | [ | |
| 2L | flavonol-3- | 2.4.1.159 | [ | |
| 6L | Glucose-4,6 dehydratase | 4.2.1.76 | [ |
EC code and locus were obtained from BRENDA [29] and MaizeGDB [30], respectively.
Figure 5Biosynthetic genes of flavone C-glycosides. The flavanones naringenin and eriodictyol are the initial substrates for the other flavonoid subgroups. There are two possible ways to generate C-glycosyl flavones, indirectly or directly, from any flavanone. The indirect pathway begins through flavanone-2-hydroxylase (ZmF2H, fnsii1, EC 1.14.14.162) opening the C-ring, producing a 3-oxo-dihydrochalcone. Then, UDP C-glycosyl transferase (ZmCGT, cgt1, EC 2.4.1.360) generates a glycosidic bond in the A-ring. Then, there is a dehydration reaction (spontaneous or enzymatic) that produces the C6-flavone glycoside. The direct pathway firstly involves flavone synthase I (ZmFNSII-2, fnsii2, EC 1.14.20.5) and flavone synthase II (ZmFNSII-1, fnsi2, EC 1.14.19.76) producing the same reaction by the addition of a double bond between C2 and C3 in the flavanone. Then, a flavone functions as a substrate for the UDP C-glycosyl transferase (ZmCGT, cgt1, EC 2.4.1.360). The enzymatic action of UDP-rhamnosyl transferase (ZmCGT, sm2, EC 2.4.1.159) and glucose 4,6 dehydratase (sm1, EC 4.2.1.76) produces either apimaysin or maysin. References: [30,43,90].
Genes that control the anthocyanin accumulation in maize.
| Gene Name | Family | Locus | Function | Regulates | Expression of Functional Allele | Paramutation |
|---|---|---|---|---|---|---|
| R2R3-MYB | 9S | + | Aleurone and scutellum | Not known | ||
| R2R3-MYB | 6L | + | Same as | Sheaths, pericarp, husk, culms, cob, and anther glumes | Yes | |
| R2R3-MYB | 1S | + (works alone) | Pericarp, silks, cob, and anther glumes | Yes | ||
| R2R3-MYB | 1S | + (works alone) | Same as | Silks and anther glumes | Not known | |
| bHLH | 10L | + | Anthers, brace roots, leaf blade tips, aleurone. and scutellum | Yes | ||
| bHLH | 2S | + | Same as | Sheaths, pericarp, husk, culms, cob, and anther glumes | Yes | |
|
| bHLH | 7S | - |
| Competition against | Not known |
| WD40 | 5L | + | Any anthocyanin pigmented tissue | Not known | ||
|
| - | 3L | - |
| Dominant inhibitor | Not known |
Symbols: + = activation, − = inhibition. References: [30,96,99,100,101,102,103].
Figure 6The regulation of the MBW complex and its influence on anthocyanin biosynthesis. (A) Environmental factors such as ultraviolet light (UV) and cold temperatures and phytohormones such as abscisic acid (ABA), salicylic acid (SA), and jasmonic acid (JA) augment the expression of the MBW complex. Meanwhile, the gibberellins (GAs) downregulate the transcription of this tripartite complex. In the case of GAs and ABA, their concentrations participate in seed development. In the seed dormancy period, ABA levels increase and the aleurone starts to accumulate anthocyanins. Mutations in the vp1 gene produce embryos insensitive to ABA, suppressing the anthocyanin biosynthesis in the aleurone and resulting in a viviparous phenotype. (B) The complete MBW is necessary to activate the anthocyanin biosynthetic genes. Some gene products such as A3 and In1 compete with the bHLH member of this transcriptional complex, suppressing the anthocyanin accumulation. (C) The anthocyanin accumulation modifies the color of the plant’s tissues, turning the vegetative tissues, aleurone, and pericarp into a purple color and turning the anthers into a red color.
Figure 7The locus p1, which regulates the biosynthesis of phlobaphenes and flavone C-glycosides, and its paramutation phenomenon. (A) UV-B produces the gene promoter demethylation of p1, with a consequent lower methylation level in the p1 promoter. (B) After demethylation, the p1 gene is expressed, and the P1 protein can function as a transcription factor. (C) P1 regulates a1 expression, leading to phlobaphene biosynthesis, and also activates essential genes for the flavone C-glucosides, such as sm1, which express the glucose 4,6-dehydratase (RHS). (D) The expression of these enzymes modifies the plant phenotype.
Beneficial health effects and action mechanisms reported for cyanidin 3-O-glucoside (C3G).
| Biological Effects | Type of Study | Dose, Time, and Model | Main Biological Findings | Ref. |
|---|---|---|---|---|
| Antitumoral | In vitro | 10 and 20 µM; 24 h; human breast cancer MDA-MB-231 and Hs-578T cells | Attenuation of breast cancer-induced angiogenesis via inhibiting VEGF up-regulation of miR-124 reduces angiogenesis (inhibiting STAT3). | [ |
| In vitro | 5, 10, 20, and 40 µM; 24 h; MDA-MB-231 and BT-549 cells | C3G induces reversion of EMT characterized by phenotype modulation with increased epithelial marker E-ca and ZO-1 and decreased mesenchymal marker vimentin, N-ca, and EMT-associated transcription factors Snail1 and Snail2. | [ | |
| In vitro and in vivo | 5, 20, 50, 150, 300, and 500 µM; 12, 24, 48, and 72 h; human breast cancer cells, melanoma cells, human embryonic kidney 293 cells, mouse and human primary melanocytes, and human samples of melanoma | C3G treatment arrested the cell cycle at the G2/M phase by targeting cyclin B1 (CCNB1) and promoted apoptosis via ERβ in both mouse and human melanoma cell lines. | [ | |
| In vivo | 10, 20, 40, and 80 µM; Chinese hamster ovary cells, human colon cancer cell lines, human breast cancer cell lines, and human melanoma cell line | C3G binds to talin (a key regulator of integrins and cell adhesion) and promotes the interaction of talin with β1A-integrin. | [ | |
| In vitro | 10 and 40 μM; 24 h; MDA-MB-231 and MDA-MB-468 breast cancer cells | The EMT inhibition is related to the upregulation of KLF4, which has been reported to be an EMT suppressor in breast cancer cells. The upregulation of KLF4 expression by C3G involves transcriptional suppression of FBXO32. It was found that FBXO32 acted as a promoter of EMT and cell migration/invasion. | [ | |
| In vivo | Drosophila malignant RafGOFscrib −/− model. | Purified C3G inhibited tumor growth invasion, distant migration and prolongs the survival of tumor flies. C3G inhibited tumor invasion by reducing the MMP1 activity and through JNK pathway. | [ | |
| In vitro | HeLa cells by evaluating cell proliferation assay (C3G doses: 0–800 μg/mL) during 24, 48, and 72 h; apoptosis (Cy3G dose: 400 μg/mL), cell cycle, cell migration, and invasion evaluation (C3G dose: 400 μg/mL). | C3G combined with DPP induced apoptosis associated with the suppressed PI3K/AKT/mTOR signaling. | [ | |
| In vivo | Induction of hepatic precancerous lesion (PCL) with diethylnitrosamine/2-acetylaminofluorene (DEN/2-AAF) in a Wistar rat model. | AFP levels were significantly decreased in the three C3G doses. | [ | |
| In vitro | C3G or its metabolite protocatechuic acid (PCA) were tested at the following doses: 100, 200, and 400 μM in HepG2 cells. | Exposure to IQ increased cytotoxicity and apoptosis in HepG2 cells, which were alleviated by C3G and PCA. | [ | |
| In vitro | Cisplatin (DDP) dose: 5 μg/mL. | C3G-DDP inhibited the activity of the antioxidant defense enzymes SOD, CAT, and GSH-Px. In parallel, C3G-DDP reduced GSH concentration while increasing the concentration of ROS and MDA. C3G-DDP reduces the expression of Nrf2 and Nrf2 target proteins: HO-1 and NQO1. | [ | |
| Antidiabetic and protection against complications of diabetes | In vitro and in vivo | 1 and 5 µM; 4 h pre-treatment of ARPE-19 cells exposed to 30 µM 4-hydroxynonenal for 24 h. 50 (mg/kg)/day for 3 weeks (2 pre-illumination and 1 post-illumination) in rabbits in which retinal damage was induced by light exposure | Decreased apoptosis, lower senescence-associated beta-galactosidase, and lower VEGF release. | [ |
| In vitro | 10 µM; 6 h; mouse colonic epithelial MCE301 cells | Higher gene expression of the Mg2+ transport carriers Trpm6 and Cnnm4. | [ | |
| In vivo | 10 and 20 (mg/kg)/day for 8 weeks in Sprague Dawley rats in which diabetes was induced with a 45 mg/kg streptozotocin dose. | Reduced fasting glycemia and insulin levels, decreased serum creatinine and BUN, and lower urinary albumin. Improved antioxidant enzyme and reduced cytokine levels. Decreased fibrosis and glomerulosclerosis in renal tissue. | [ | |
| In vitro | 100 µM; 24 h; human corneal epithelial cells (HCEC 6510) previously exposed to 10 µg/mL of LPS for 24 h | Reduced apoptosis and decreased production of cytokines. | [ | |
| In vivo | 1.6 mg/mL in drinking water (∼6.4 mg/day), for 3 or 20 weeks, in C57BL/6J male mice fed a low- or high-fat diet | Decreased weight gain for high-fat diet, improved glucose tolerance, reduced hepatic and plasma triglycerides, and modulated hepatic FGF21 levels. | [ | |
| In vitro and in vivo | 20 µM; 24 h; HUVEC cells exposed for 1 h to 100 ng/mL TNF-alpha before treatment with C3G. | Reduced damage in the intima media; decreased levels of circulating cholesterol, low-density lipoprotein, and triglycerides; and increased high-density lipoprotein. Reduced levels of cytokines and lowered apoptosis rates. Higher expression of SIRT1. | [ | |
| In vitro | 20 µM; 48 h (+1 h pre-treatment); lens epithelial SRA01/04 cells exposed to 100 mM glucose and Sprague Dawley rat lens tissue exposed to 50 mM glucose. | Reduced apoptosis rates, decreased NFkB levels, and lowered Cox-2 protein expression. Decreased opacity of rat’s lens tissue. | [ | |
| In vitro | 5 and 10 µM pre-treatment; 24 h; 3T3-L1 cells and human SGBS cells exposed to 1 mM or 500 µM palmitate for 24 h | Reduced lipid content, lower PPARgamma and nuclear NFkB protein levels, improved levels of insulin signaling targets, and higher Adipoq gene expression. | [ | |
| In vivo | 10 and 50 µM; 24 h; HepG2 pre-treated with 400 µM palmitic acid and 400 µM oleic acid for 24 h. 50 mg/day; 8 weeks; male C57BL 6J mice previously fed an HFD for 4 weeks and 8 additional weeks of HFD during C3G treatment. | Reduced plasma and liver triglycerides, reduced fatty acid synthesis, lower fasting plasma glucose and insulin, higher cell glucose uptake, activation of PPAR-alpha. | [ | |
| Liver disease and hepato-protection | In vitro and in vivo | 100 µM; 12 h; HepG2 or AML-12 cells co-treated with 400 µM palmitic acid 0.2% ( | Reduced liver steatosis, lower fasting glucose and insulin levels, reduced NLRP3 inflammasome, higher antioxidative enzyme levels, lower ROS levels, increased mitophagy. | [ |
| In vitro | 5 µg/mL; 12 h; HepG2 cells pre-exposed to 4 µM hydrogen peroxide for 6 h | Decreased ROS levels, increased glutathione content, and higher catalase activity. Increased Nrf2 and Keap1 protein levels. | [ | |
| In vitro | 2.5–10 µM; 24 h; HepG2 cells previously treated with 400 µM hydrogen peroxide | Increased cell viability and antioxidative machinery. Decreased ROS, apoptosis rates, and apoptosis-related proteins. | [ | |
| In vitro and in vivo | 200 (mg/kg)/day; 8 weeks; male C57BL 6J mice fed an HFC diet and 5% ethanol drinking solution during the C3G treatment. | Reduced liver lipid content, lower levels of proinflammatory cytokines and inflammasome proteins, reduced NFkB protein expression and acetylation, and increased SIRT1 protein levels. | [ | |
| Colitis and gastrointestinal alterations | In vivo and in vitro | 1 ug i.p. on days 0, 3, and 6 of model induction; C57BL 6J mice in which colitis was induced with drinking water containing 3.5% of dextran sulfate sodium for 7 days. 1 µg/mL; 24 h; peritoneal macrophages activated with 1 ug mL−1 of LPS. | Reduced cytokine gene expression in the colon, induction of Treg cells, and reduction of peritoneal CD169+ macrophages. | [ |
| In vivo | 500 and 1000 mg/kg of diet; 8 weeks; male Wistar rats in which dysbiosis and intestinal damage were parallelly induced with 20 mg/kg 3-chloro-1,2-propanediol for 8 weeks | Improved histological features, modulation of gut microbiota. | [ | |
| In vivo and in vitro | 50, 100, or 200 µmol/kg; 3 days; female BALB c mice in which colitis was induced with 2.5 mg of 2,4,6-trinitrobenzen-osulfonic acid 12 h after the first dose of C3G. 50 and 100 µmol/L; 24 h pre-treatment; LPS-induced Caco-2 cells with 100 ng/mL for 24 h. | Prevention of histological damage, reduction of proinflammatory cytokines, and suppression of nitric oxide production. | [ | |
| In vitro | 10 or 20 µmol/L; 24 h pre-treatment; Caco-2 cells induced with palmitic acid 100 µmol/L for 6 h | Decreased nuclear NFkB, reduction of cytokine IL6 and IL8 gene expression and COX2 protein, decrease in ROS, and increase in Nrf2 levels. | [ | |
| Neuroprotective | In vitro | 2.5, 5, or 10 µmol/L; 4 h pre-treatment; microglial BV2 (macrophage) cells stimulated with 1 μg/mL LPS for 24–48 h | Decreased cytokine levels, reduced iNOS mRNA levels and lower NO production, suppression of NFkB activation and p38 signaling pathway, decreased neurotoxicity and apoptosis in PC12 cells exposed to conditioned media from LPS-activated BV2 cells. | [ |
| In vitro | 0.05, 0.1, 0.25, 0.5, or 1 µmol/L; 24 h pre-treatment; HT22 neuronal cells exposed to 5 mM glutamate for 18 h | Reduction of apoptosis, decrease in ROS, increase in Nrf2 levels and antioxidative gene expression, reduction of ER stress biomarkers. | [ | |
| In vitro | 1, 3, or 9 µmol/L; 24–48 h; PC12 neuronal cells exposed in parallel to amyloid beta fibrils | Increased cell viability, decreased necrosis, reduced ROS levels. | [ | |
| In vitro | 30 mg kg-1 day-1; 38 weeks; APPswe/PS1dE9 mice modeling Alzheimer’s disease | Differential gene expression in the spleen of the treated animals, including upregulation of antioxidant and immune system-related molecular targets. | [ | |
| Reproductive health | In vitro | 5, 20, 40, 80, or 160 µmg/L; 2 h pre-treatment; Leydig R2C cells exposed to 44.8 µmol/L cadmium sulfate for 24 h | Increased cell viability, reduced ROS levels, protection of mitochondrial potential, increased StAR protein and progesterone levels. | [ |
| In vivo | 500 mg/kg of chow diet; 10, 20, or 30 days; Kunming male mice treated with 5 (mg/kg)/day of cadmium chloride | Decreased levels of circulating FSH and testosterone, increased LH circulating levels, differential modulation of gene expression in the hypothalamus, increased expression of proteins involved in testosterone biosynthesis. | [ | |
| Respiratory system, antiviral, and anti-SARS-CoV2 | In vivo | Diet containing 0.4% C3G (~1.2 mg/day); 25 days; asthma model of BALB/c mice sensitized to ovalbumin intraperitoneally (20 μg on days 0, 7, and 14) and nasally (1% aerosols on days 21–25) | Decreased number of peripheral eosinophils; reduced inflammatory infiltration in the lungs; lower levels of IL-4, IL-5, and IL-13; inhibition of IL-4Ra-STAT6 pathway. | [ |
| In silico and in vitro | 3–200 µmol/L; papain-like protease assay for determination of deubiquitinase activity | The molecular docking prediction showed a potential binding activity to the papain-like protease of SARS-CoV-2, concentration-dependent inhibition of papain-like protease deubiquitinase activity. | [ | |
| In silico and in vitro | 3–200 µmol/L; papain-like protease assay for determination of total protease activity | Molecular docking prediction of binding to the papain-like protease of SARS-CoV2. Concentration-dependent inhibition of papain-like protease total protease activity. | [ | |
| In vivo and in vitro | 200 or 400 mg/kg bw; oral administration from days 2–28; Sprague Dawley male rats injected intraperitoneally with monocrotaline 60 mg/kg bw on day 1 to induce a model of pulmonary artery hypertension. | Reduction of hemodynamic indicators of pulmonary artery hypertension, improved histological features and blood oxygenation, reduction of cytokines levels, reduced markers of proliferation in PASMC, inhibition of TGF-beta1-p38 MAPK-CREB signaling pathway. | [ | |
| Anti-inflammatory and immune system modulation | In vivo and in vitro | 25 mg/kg; two tail-vein injections per week for a total of six injections starting ten days after the secondary immunization; Sprague-Dawley male rats in which arthritis was induced by three injections of bovine type II collagen. | Increased Treg cells and decreased CD38+ NK cell proportion in blood and synovial fluid in murine model, increased apoptosis and decreased proliferation in human rheumatoid arthritis synovial fibroblasts, decrease in proinflammatory cytokines. | [ |
| In vivo | 10 (mg/kg)/day; 15 weeks; spontaneously hypertensive male rats and Wistar-Kyoto rats. | No differences were observed either in the spleen weights or in the proportions of splenic T-cells and helper T-cells; modulation of CD62Lhi, CD62Llo, CD62L-, CD25+, and T-reg cells dependent on the genotype. | [ | |
| In vitro and in vivo | 25, 50, 100, and 250 µmol/L, RBL-2H3 cells sensitized with anti-DNP IgE and exposed to DNP-BSA antigen 100 and 200 µmol/kg bw, orally administered 1 h before antigen exposure, and 40 mg/kg bw, intravenous administration 1 h before antigen challenge, male ICR mice sensitized with anti-DNP IgE (100 ng injection in the ear) 24 h before the experiment and then challenged with DNP-BSA antigen (140 µg/mouse). | Dose-dependent inhibition of histamine and beta-hexosaminidase release, decreased ear tissue response (measured as extravasation) after antigen challenge. | [ | |
| Other studies | In vitro | 80 µmol/L; 2 h pre-treatment; primary human dermal fibroblast irradiated with 12 J/cm2 UVA light and treated with 3-methyladenine | Decreased apoptosis, increased expression of autophagy markers, reduced ROS levels. | [ |
| In vivo | 100 mg/kg body weight, oral administration before induction; Wistar rats injected with 1 mL/kg of 5% taurocholate to induce a model of severe acute pancreatitis | Increased colonic motility, decreased serum levels of H2S and pro-inflammatory cytokines, activation of mTOR signaling, reduced protein levels of cystathionine-gamma-lyase. | [ | |
| In silico | Molecular modeling to assess for potential interactions between C3G and the advanced glycation end product receptor and its ligands | The results suggest a potential interaction and subsequent inhibition of the receptor for advanced glycation end products. | [ | |
| In vitro | 25–400 µM; 24–72 h; primary human osteoblasts and MC3T3-E1 osteoblast murine cell line | Increased cell proliferation, increased mineralization activity, activation of ERK1/2 signaling pathway, increased osteocalcin protein and mRNA levels. | [ | |
| In vitro | 1.25, 2.5, and 5 µmol/L; 24 h co-treatment or 2 h pre-treatment; primary human articular chondrocytes exposed to advanced glycation end products 10 µg/mL for 24 h (parallel to C3G treatment) or 10 min (after 2 h pre-treatment). | Reduced protein and mRNA expression levels of matrix metalloproteinases, decreased NF-kB signaling, reduced ERK/MAPK signaling activation. | [ | |
| In vitro | 20 µmol/L; six-day treatment renewed every 48 h; human amniotic epithelial cells | Differential modulation of genes including targets involved in adipocyte differentiation and muscle activity. | [ |
EMT = epithelial–mesenchymal transition, CCNB1 = cyclin B1, DDP = cis-diamminedichloroplatinum, CAT = catalase, SOD = superoxide dismutase, GSH-Px = glutathione peroxidase, Nrf2 = nuclear factor erythroid 2-related factor-2, Keap1 = Kelch-like ECH-associated protein 1, HO-1 = heme oxygenase-1, NOQ1 = NAD(P)H quinone dehydrogenase 1, PCA = protocatechuic acid, MDA = malondialdehyde, TMT = tandem mass tag, VEGF = vascular endothelial growth factor.